在印尼高血压患者中,ACE插入/删除基因多态与卡波普利尔有效性的相关性
Dewa A S Handani1,2, Adam Hermawan3, Zullies Ikawati4
1Faculty of Pharmacy, Universitas Mahasaraswati Denpasar, Bali, Indonesia.
Pharmacogenomics
|July 29, 2024
概括
血管激素转化酶插入/删除 (ACE I/D) 基因多态性并不能预测印尼高血压患者中卡波普利的有效性. 这一发现表明,ACE I/D在指导使用这种ACE抑制剂治疗高血压时具有有限的效用.
科学领域:
- 药物基因组学 药物基因组学
- 心血管医学 心血管医学
- 遗传学 是一个遗传学.
背景情况:
- 高血压在印度尼西亚是一个重要的公共卫生问题.
- 印尼高血压患者中很大一部分对ACE抑制剂治疗的反应不佳.
研究的目的:
- 调查印尼高血压患者的ACE I/D多态性和卡波普利尔治疗反应之间的关联.
- 评估ACE I/D基因型在卡普托普里尔后降低血压的预测价值.
主要方法:
- 进行了一项多中心病例控制研究.
- 用PCR和电泳进行了ACE I/D多态的基因定型.
- 血压变化测量在接受卡普托普利的高血压患者.
主要成果:
- 在ACE I/D基因型频率或基因组分布之间没有发现显著差异.
- 降低血压在三个ACE I/D基因型中没有显著差异.
- 统计分析没有支持ACE I/D和卡波普里尔有效性之间的显著关联.
结论:
- 在印尼的高血压患者中,ACE I/D多态性与血压降低没有显著的关联,这些患者接受了卡普托普利的治疗.
- 这些发现表明,ACE I/D基因型在优化该人群中的卡波普利尔治疗方面具有有限的预测效用.
相关概念视频
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
578
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
578
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413
Antihypertensive Drugs: Direct Renin Inhibitors
521
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
521
Antihypertensive Drugs: Angiotensin II Receptor Blockers
674
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
674
Dose-Response Relationship: Potency and Efficacy
4.3K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.3K
Time Course of Drug Effect
2.0K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.0K


